Latest Manufacturing News

Minbos Resources reports strong 2024-25 field trial results for its phosphate fertilizer PRIMEIRO™ in Angola, while expanding its product range with PRIMEIRO PLUS+, a blended NPKS solution tailored to local soils and crops.

ASPI Isotopes Inc. has proposed a scheme to acquire all Renergen shares at a 41.3% premium, aiming to create a global critical materials powerhouse. The deal, subject to shareholder and regulatory approval, will delist Renergen from multiple exchanges.

Mesoblast reports positive FDA progress on accelerated approval for Revascor in ischemic heart failure and plans a pivotal trial to extend Ryoncil’s label to adults with graft versus host disease, while its US commercial launch outpaces expectations.

HITIQ has partnered exclusively with Shock Doctor to launch the PROTEQT instrumented mouthguard, aiming to transform concussion management worldwide. The company also initiates a $2.92 million rights issue to fuel this ambitious rollout.

EVE Health Group has completed its acquisition of Nextract Pty Ltd, positioning itself to enter the lucrative erectile dysfunction and dysmenorrhea markets with innovative drug delivery technologies.

AnteoTech secures a significant purchase order from the Serum Institute of India, driving its Life Sciences unit toward a projected 130% sales increase in FY2025 despite some project delays.

BPH Global Ltd has completed its second seaweed sale under a strategic partnership in Indonesia, marking steady progress in its supply network expansion and operational execution.

Cleo Diagnostics unveils a pioneering blood test for early ovarian cancer detection, boasting superior accuracy to existing methods and targeting a significant U.S. market opportunity.

Bioxyne Limited has raised its FY2025 revenue guidance to $28 million, driven by explosive growth in Australian pharmaceutical manufacturing and the upcoming commercial production of MDMA capsules. The company is also making strides in expanding its footprint across Europe.

Clover Corporation has upgraded its FY25 earnings forecast, expecting net profit after tax to exceed market consensus by around 20%, driven by strong sales and operational improvements.

Telix Pharmaceuticals showcased its global theranostic radiopharmaceutical portfolio, highlighting FDA approvals, clinical progress, and a robust commercial expansion plan at its 2025 Investor Day.

EVE Health Group has launched a $1.5 million capital raise alongside the acquisition of biotech firm Nextract, aiming to expand its footprint in health and pharmaceutical products focused on erectile dysfunction and period pain.